DGAP-Adhoc: MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with chemotherapy announced


MOLOGEN AG  / Key word(s): Patent

02.09.2015 21:13

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc notification according to § 15 WpHG

MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with
chemotherapy announced

Berlin, September 2, 2015 - MOLOGEN AG  announces that the United States
Patent and Trademark Office (PTO) has declared that it will grant a patent
(Notice of Allowance) for the combined use of the lead product,
immunotherapy MGN1703, with a chemotherapeutic agent. MGN1703 is currently
being tested in a phase III IMPALA pivotal study, both as a monotherapy and
in combination with chemotherapy. The patent will be granted for the USA
and would, in the event of market approval there, cover the dosing regimen
for MGN1703 in combination with chemotherapy. In addition, the patent will
last probably several years longer than the initial patent for MGN1703
(substance patent) and would therefore permit a longer exclusive
commercialization than the initial patent.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.


02.09.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      MOLOGEN AG
              Fabeckstraße 30
              14195 Berlin
              Germany
Phone:        030 / 841788-0
Fax:          030 / 841788-50
E-mail:       presse@mologen.com
Internet:     www.mologen.com
ISIN:         DE0006637200
WKN:          663720
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
              Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------